Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 06, 2017

Trastuzumab Plus Weekly Paclitaxel and Carboplatin as Neoadjuvant Treatment for HER2-Positive Breast Cancer

European Journal of Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Cancer
Trastuzumab in Combination With Weekly Paclitaxel and Carboplatin as Neo-Adjuvant Treatment for HER2-Positive Breast Cancer: The TRAIN-Study
Eur. J. Cancer 2017 Mar 01;74(xx)47-54, MS van Ramshorst, E van Werkhoven, IAM Mandjes, M Schot, J Wesseling, MJ TFD Vrancken Peeters, JM Meerum Terwogt, M EM Bos, HM Oosterkamp, S Rodenhuis, SC Linn, GS Sonke

Further Reading